Condition: EGFR Mutation Positive Non-small Cell Lung Cancer · EGFR Mutated Non-small Cell Lung Cancer Patients · Sponsor: Nuvectis Pharma, Inc.
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
This description comes directly from the study's public registry record.
Erin Belshaw · 12016278129 · ebelshaw@nuvectis.com
Shay Shemesh · sshemesh@nuvectis.com
Always discuss trial participation with your own doctor first.
| Maryland Oncology Hematology | Calverton, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Willamette Valley Cancer Institute and Research Center | Eugene, Oregon, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| NEXT Houston | Houston, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07315113